Peptide Dosing,made clear.

The basics are simple: strength, liquid volume, concentration and target amount. Choose the tool that matches what you actually have in front of you.

Arithmetic only — not a dose recommendation.

These tools convert numbers you already know. They do not choose a target amount. For pens, you must also confirm the exact device type and click/dose-selector system; for vials, confirm concentration and syringe type before converting between mg, mL and syringe units.

Important if you are using a pen

Using a peptide pen? Start here.

Do not guess the device, click scale or technique from appearance. Watch the pen guide and confirm the exact device before using click calculations.

Choose your format

What the numbers mean

Read the label before you calculate.

Vial label

10 mg

total peptide

mg = amount of peptide

Look on the vial label for the total amount, for example 10 mg.

2 mL

liquid added

mL = liquid volume

mL describes liquid. It is not the same thing as mg.

100 units = 1 mL

Units = syringe volume marks

On a U-100 syringe, the unit scale is another way of measuring liquid volume.

1 mg

equals

1,000 mcg

mg and mcg are both amounts

mcg is simply a smaller unit. The calculator converts between them.

Core formula

Concentration = total peptide ÷ liquid volume

Example: 50 mg in 2.5 mL = 20 mg/mL. If a target amount is selected, volume = target amount ÷ concentration. On a U-100 syringe, 1 mL corresponds to 100 units.

Simple calculator

Use the numbers in front of you.

Opened from Ipamorelin + CJC no DAC. The profile context does not change the arithmetic or choose a target amount.

4. Result

—

Does body size change the amount?

Sometimes. But there is no universal peptide rule based on height or weight.

Some approved medicines use fixed amounts. Others explicitly use body weight, such as mg/kg, or body-surface area, which can use both height and weight. Height by itself is not a general dosing rule.

The Pep Report therefore never scales a target amount automatically from body size. If a study, prescribing label or qualified clinician uses a weight- or BSA-based method, start with that known amount and use our calculator only for the arithmetic conversion.

FDA guidance on weight/BSA-based dosing

Reference cards

Common research reference ranges.

These cards put The Pep Report’s research reference amounts and schedules in one place. They are educational references rather than individualized recommendations. Open a peptide to see the evidence, formulation context and detailed dosing notes behind the number.

Human component data · combination unproven

Ipamorelin + CJC no DAC

Reference

CJC 100–300 mcg + Ipamorelin 100–300 mcg

Daily · 8–12 weeks

View details →
Human topical + preclinical

GHK-Cu

Reference

1–2.5 mg

3× weekly · 6–8 weeks

View details →
Component evidence only · blend unvalidated

GLOW

Reference

1.4–4.2 mg per injection; 2.8 mg is a commonly cited reference point

Daily initially, then 5×/week, then 2–3×/week in the cited 12-week protocol · 12 weeks

View details →
Component evidence only · blend unvalidated

KLOW

Reference

1.6–4.8 mg per injection

Daily initially, then 5×/week, then 2–3×/week in the cited 12-week protocol · 12 weeks

View details →
Cell + animal research · no established human drug data

KPV

Reference

200–500 mcg daily

Daily · 4–8 weeks

View details →
Small early human studies · unapproved

Melanotan II

Reference

250–500 mcg daily

Daily · 1–4 weeks

View details →
Human endogenous biology + preclinical treatment data

MOTS-c

Reference

5–10 mg

2–3× weekly · 8–12 weeks

View details →
Human biochemical data · wellness outcomes unproven

NAD+

Reference

50–250 mg

2–3× weekly · 2–12 weeks

View details →
Approved medicine · phase 3 human evidence

PT-141

Reference

1.75 mg as needed

As needed · On-demand

View details →
Phase 3 human trials · investigational

GLP-3 Retatrutide

Reference

0.3–12 mg weekly

Weekly · 12–48 weeks

View details →
Small human anxiety studies · investigational in U.S.

Selank

Reference

250–500 mcg daily

Daily · 2–4 weeks

View details →
Limited human intranasal evidence · investigational in U.S.

Semax

Reference

200–600 mcg daily

Daily · 2 weeks

View details →
FDA accelerated approval · human clinical evidence

SS-31 / Elamipretide

Reference

5–10 mg daily

Daily · 8–12 weeks

View details →
Approved medicine · randomized human evidence

Tesamorelin

Reference

1–2 mg daily

Daily · 12–16 weeks

View details →
Direct animal combination study · no controlled human blend evidence

BPC-157 / TB-500 (Wolverine)

Reference

BPC-157 250–500 mcg daily + TB-500 1–2.5 mg 2–3× weekly

Mixed by component · 4–6 weeks

View details →
Mostly preclinical · very limited human data

BPC-157

Reference

250–500 mcg daily

Daily · 4–6 weeks

View details →
Preclinical · no established human exposure data

TB-500

Reference

1–2.5 mg

2–3× weekly · 4–6 weeks

View details →
Approved medicine · extensive human evidence

Semaglutide

Reference

0.25 mg weekly start; maintenance 0.5–2.4 mg weekly, up to 7.2 mg for certain adults

Once-weekly injection; approved oral formulations are taken once daily

View details →